Py-MAA-Val-Cit-PAB-MMAE

Modify Date: 2025-09-24 14:27:00

Py-MAA-Val-Cit-PAB-MMAE Structure
Py-MAA-Val-Cit-PAB-MMAE structure
Common Name Py-MAA-Val-Cit-PAB-MMAE
CAS Number 2247398-68-9 Molecular Weight 1446.79
Density N/A Boiling Point N/A
Molecular Formula C72H111N13O16S Melting Point N/A
MSDS N/A Flash Point N/A

 Use of Py-MAA-Val-Cit-PAB-MMAE


Py-MAA-Val-Cit-PAB-MMAE (AAJ8D6-PY-Val-Cit-MMAE) is an ADC Linker of Zapadcine-3a. Zapadcine-3a is an anti-TRAILR2 ADC with broad spectrum, and antineoplastic effect. Zapadcine-3a can be swallowed up into lysosome of tumor cells by binding to TRAILR2. Then Zapadcine-3a releases small molecular compound to specifically kill various TRAILR2-pos. Zapadcine-3a potently eradicates tumor cells and cures tumor[1].

 Names

Name Py-MAA-Val-Cit-PAB-MMAE

 Py-MAA-Val-Cit-PAB-MMAE Biological Activity

Description Py-MAA-Val-Cit-PAB-MMAE (AAJ8D6-PY-Val-Cit-MMAE) is an ADC Linker of Zapadcine-3a. Zapadcine-3a is an anti-TRAILR2 ADC with broad spectrum, and antineoplastic effect. Zapadcine-3a can be swallowed up into lysosome of tumor cells by binding to TRAILR2. Then Zapadcine-3a releases small molecular compound to specifically kill various TRAILR2-pos. Zapadcine-3a potently eradicates tumor cells and cures tumor[1].
Related Catalog
Target

CD262

References

[1]. Zheng Dexia, et al. Anti-tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAILR2) antibody-drug conjugate (ADC) and its pharmaceutical application in antineoplastic therapy: China, CN108452320. 2018-08-28.

 Chemical & Physical Properties

Molecular Formula C72H111N13O16S
Molecular Weight 1446.79
InChIKey ASDXMJBJAKMFHO-NGASZDMPSA-N
SMILES C=CC(=O)N1CN(C(=O)C=C)CN(C(=O)CCSCC(=O)NC(C(=O)NC(CCCNC(N)=O)C(=O)Nc2ccc(COC(=O)N(C)C(C(=O)NC(C(=O)N(C)C(C(C)CC)C(CC(=O)N3CCCC3C(OC)C(C)C(=O)NC(C)C(O)c3ccccc3)OC)C(C)C)C(C)C)cc2)C(C)C)C1
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.